Facts matter: Sign up for the free Mother Jones Daily newsletter. Support our nonprofit reporting. Subscribe to our print magazine.


Everything is good news this month. My M-protein level continues to decline, which means the level of cancerous plasma cells in my bone marrow is declining too. I’m still a long way from zero, but heading in the right direction.

At the same time, my immune system rebounded. Last month I was down to 1,300, which is uncomfortably close to the danger level of 1,000. This month I’m back up to 1,900, so perhaps March was just an outlier.

In other news, the Institute for Clinical and Economic Review has released a report evaluating the tsunami of new multiple myeloma treatments that have been brought to market recently. Three of them received a grade of B+, which sounds pretty good—although it turns out to mean only “moderate certainty of a small net health benefit.” In numbers, that’s an increased survival rate of 5-9 months. And do you remember all those recent news reports about how pricey new cancer treatments are these days? This is now more than an intellectual curiosity for me. These new drugs are really, really expensive: upwards of $400,000 per year of extra life.

And who pays for this? In the narrowest sense, Mother Jones. In a broader sense, everyone who pays premiums to Kaiser Permanente. And in the broadest sense of all, everyone in the country. So you have to decide: is it worth $400,000 to have Kevin Drum around for an extra year? That depends a lot on whether you happen to be Kevin Drum, doesn’t it?

But there’s no need to decide yet. It will likely be years before I need a third-line treatment, and by then maybe something better will be around. Personally, I’m counting on nanobots, so get cracking, nanotechnologists.

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate